论文部分内容阅读
培美曲塞是礼来公司研制成功的新一代抗代谢类抗癌新药,于2004年2月被美国食品药品监督管理局(FDA)批准用于治疗恶性胸膜间皮瘤,随后又被批准用于晚期非小细胞肺癌的二线治疗,英文商品名为Alimta?,中文商品名为力比泰。培美曲塞是一种多靶点的抗癌药物,它发挥作用的靶点均为叶酸代谢途径中的几个关键酶,而该途径能够显著影响癌细胞的DNA合成和癌症的生长。因此理论上,培美曲塞对癌症的抑制作用应该十分显著,并且对多种癌症可能均有治疗效果。事实上也正是如此。培美曲塞被最早批准用于治疗晚期胸膜间皮瘤,该肿瘤的恶性程度高、进展迅速、对放化疗等多种治疗手段均疗效不佳,而培美曲塞在该肿
Pemetrexed is a new generation of anti-cancer anti-cancer drugs developed by Eli Lilly and Company. It was approved by the U.S. Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma in February 2004 and subsequently approved In the second-line treatment of advanced non-small cell lung cancer, the English name of the product is Alimta®, and the Chinese name of the product is Libitai. Pemetrexed is a multi-targeted anticancer drug that targets all of several key enzymes in the folate metabolic pathway, and this pathway can significantly affect cancer cell DNA synthesis and cancer growth. Therefore, theoretically, pemetrexed should have a significant inhibitory effect on cancer and may have a therapeutic effect on a variety of cancers. In fact it is also true. Pemetrexed is the earliest approved for the treatment of advanced pleural mesothelioma, the high degree of malignancy of the tumor, the rapid progress of the treatment of radiotherapy and chemotherapy and other means are ineffective, and pemetrexed in the swollen